13:53 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Antibody-drug conjugate targeting ALK could treat neuroblastoma

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Cell and mouse studies identified an ALK-targeting antibody-drug conjugate (ADC) that could help treat neuroblastoma. The ADC consists of an anti-ALK mAb linked to the generic chemotherapy drug thienoindole....
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
21:32 , Mar 14, 2019 |  BC Extra  |  Preclinical News

Antibody-drug conjugate against ALK could selectively treat neuroblastoma

Researchers from CHOP and Celldex showed that an antibody-drug conjugate targeting ALK selectively kills neuroblastoma cells, suggesting the ADC could have a better safety profile than marketed drug dinutuximab. Unituxin dinutuximab from United Therapeutics Corp....
18:23 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Celldex reports Phase I/II data for varlilumab plus Opdivo in solid tumors

Celldex Therapeutics Inc. (NASDAQ:CLDX) reported data from 90 patients with advanced refractory solid tumors in a Phase I/II trial showing that varlilumab (CDX-1127) plus PD-1 inhibitor Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) was well...
18:29 , Apr 20, 2018 |  Clinical Results  |  Clinical Results

Celldex discontinues development of glembatumumab vedotin after TNBC failure

Celldex Therapeutics Inc. (NASDAQ:CLDX) said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb METRIC trial to treat metastatic triple-negative breast cancer (TNBC)...
19:11 , Apr 16, 2018 |  BC Extra  |  Clinical News

Celldex routed after TNBC failure

Celldex Therapeutics Inc. (NASDAQ:CLDX) fell $1.39 (65%) to $0.76 on Monday after it said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb...
16:42 , Apr 5, 2018 |  BC Innovations  |  Finance

Public funding highlights

Public funding highlights Selected developments and initiatives in 1Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
01:21 , Jan 12, 2018 |  BC Innovations  |  Translation in Brief

In the twenties

A Cancer Cell study from University of Southampton and Celldex Therapeutics Inc. (NASDAQ:CLDX) researchers suggests combining CD27 agonists with tumor-targeting mAbs could help myeloid cells attack a broad array of cancers. The partners are testing...
00:04 , Sep 22, 2017 |  BC Extra  |  Company News

Management tracks: Unity, Shield, Tusk

Anti-aging company Unity Biotechnology Inc. (San Francisco, Calif.) hired Bob Goeltz as CFO, Doug Rich as SVP of operations and Tamara Tompkins as general counsel. Goeltz will replace interim CFO John Smither, and Tompkins will...
22:38 , Jul 20, 2017 |  BC Innovations  |  Finance

Sharpless edge for NCI

The National Cancer Institute is poised to enter a new phase, under the leadership of Norman (Ned) Sharpless, following the June 9 announcement by the White House of the president’s choice to fill the large...